作者: S. B Mossad
关键词:
摘要: FluMist—a cold-adapted, live-attenuated, trivalent, intranasal influenza virus vaccine approved by the US Food and Drug Administration on June 17, 2003—has been shown to be safe effective, but its role in general prevention of is yet defined. Intranasal administration expected more acceptable than parenteral, particularly children, potential for shedding live may pose a risk anyone with compromised immune system.